Now showing items 1-3 of 3

    • Current and Future Therapeutic Targets for Pulmonary Arterial Hypertension 

      Fraidenburg, Dustin; Yuan, Jason (Mary Ann Liebert, 2013-06)
      Pulmonary arterial hypertension (PAH) remains a poorly understood disorder with dire consequences. Progression of disease often leads to right heart failure and death without lung transplantation. Limited therapeutic ...
    • Enhanced Ca2+-sensing receptor function in pulmonary hypertension 

      Yamamura, A.; Yamamura, H.; Yuan, J.X. (Pharmaceutical Society of Japan, 2013)
      Pulmonary arterial hypertension (PAH) is a rare, progressive, and fetal disease. The five-year survival rate after diagnosis is ~50%. In Japan, PAH is listed in the Specified Rare and Intractable Diseases. Pulmonary vascular ...
    • Reduced expression of angiotensin I-converting enzyme in Caveolin-1 knockout mouse lungs 

      Maniatis, Nikolaos A.; Balyasnikova, Irina V.; Metzger, Roman; Castellon, Marciela; Visintine, David J.; Schwartz, David E.; Minshall, Richard D.; Danilov, Sergei M. (Elsevier, 2010-09)
      Reduced lung capillary expression of angiotensin I-converting enzyme (ACE), a key enzyme in cardiovascular pathophysiology, and of caveolin-1, an important regulator of endothelial cell signalling, has been demonstrated ...